Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of “Moderate Buy” from Brokerages

Personalis, Inc. (NASDAQ:PSNL) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $11.50.

Several equities analysts recently weighed in on PSNL shares. Morgan Stanley dropped their price target on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 5th. Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a research note on Sunday, March 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a report on Thursday, January 22nd. Guggenheim lifted their target price on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, BTIG Research upped their price target on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th.

Institutional Trading of Personalis

Institutional investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. lifted its position in shares of Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after purchasing an additional 7,896,714 shares in the last quarter. ARK Investment Management LLC boosted its holdings in Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after purchasing an additional 802,268 shares during the last quarter. AIGH Capital Management LLC grew its position in Personalis by 4.5% in the 3rd quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock worth $25,376,000 after purchasing an additional 168,143 shares in the last quarter. Aberdeen Group plc grew its position in Personalis by 36.1% in the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after purchasing an additional 861,948 shares in the last quarter. Finally, Kennedy Capital Management LLC increased its stake in Personalis by 196.2% in the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after buying an additional 1,281,695 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

Personalis Trading Up 4.9%

PSNL opened at $7.12 on Wednesday. Personalis has a 1-year low of $2.83 and a 1-year high of $11.50. The company has a market cap of $744.98 million, a price-to-earnings ratio of -7.82 and a beta of 2.02. The company’s fifty day moving average price is $8.75 and its two-hundred day moving average price is $8.27.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.05. The firm had revenue of $17.35 million during the quarter, compared to analysts’ expectations of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. As a group, equities analysts forecast that Personalis will post -1.4 earnings per share for the current fiscal year.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.